New insider Cho Esther claimed ownership of 44,000 shares (SEC Form 3)
$KROS
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 08/06/2025 |
3. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 44,000(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Stock Option (Right to Buy) | (2) | 05/03/2030 | Common Stock | 20,968 | $29.02 | D | |
| Employee Stock Option (Right to Buy) | (2) | 01/09/2031 | Common Stock | 20,000 | $70.93 | D | |
| Employee Stock Option (Right to Buy) | (3) | 01/20/2032 | Common Stock | 25,000 | $46.3 | D | |
| Employee Stock Option (Right to Buy) | (4) | 02/15/2033 | Common Stock | 50,000 | $54.38 | D | |
| Employee Stock Option (Right to Buy) | (5) | 02/12/2034 | Common Stock | 50,000 | $56.18 | D | |
| Explanation of Responses: |
| 1. Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person continuing to provide service through each such date. |
| 2. Immediately exercisable. |
| 3. One-fourth (1/4th) of the shares subject to the option vested on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| 4. One-fourth (1/4th) of the shares subject to the option vested on February 16, 2024, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| 5. One-fourth (1/4th) of the shares subject to the option vested on February 13, 2025, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
| /s/ Esther Cho | 08/15/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||